I was thinking, this whole statement was aimed at Europe. I mean it seemed, at the time, a bit bold for the FDA, but maybe the everything there was in disarray and nobody cared. I think we were already moving toward Europe.

Quote:

---

Although mTNBC typically has a poor prognosis, observed survival rates at 12, 24, and 36 months after treatment with leronlimab compare favorably with reported life expectancy after treatment with currently approved therapies. In addition, the Company confirmed that a small group of patients who failed treatment after developing metastatic disease survived more than 36 months after receiving leronlimab, are alive today, and currently identify as having no evidence of ongoing disease.

---